List view / Grid view
While the full potential of gene therapies continues to be realised, their successes in rare diseases promote them as a promising treatment modality. Dr Gaurav Shah, Chief Executive Officer of Rocket Pharmaceuticals discusses the future of gene therapies as well as the company’s progress in in vivo and ex vivo programmes.
In this article, Dr Mary Spellman, Chief Medical Officer and Senior Vice President of R&D at Castle Creek Biosciences, discusses how a versatile dual platform of ex vivo and in vivo gene therapy technologies is being utilised for the development of novel gene therapies for a broad range of rare…
This ebook features articles from gene therapy specialists that look at current platforms as well as the future of promising modalities for gene therapies. It also tackles novel stem cell technology considerations and gives insight into the careful balancing act between efficacy and safety in gene therapy.
Researchers have developed a computational DNA droplet with the ability to recognise specific combinations of chemically synthesised microRNAs that act as biomarkers of tumours.
Researchers have developed a novel class of therapeutics, called feedback disruptors, that could have the potential to be resistance-proof drugs.
Scientists have developed a deep learning-based model trained on drug-induced gene expression signatures to predict drug-drug interactions.
In this episode, experts explore the benefits of 3D imaging and the important considerations for organoid workflows in research and drug development.
Scientists have gained new insights into the way G protein-coupled receptors operate, a step toward the development of improved drugs with fewer side effects.
A new screening assay could be used to identify new drugs to treat resistant forms of prostate cancer.
Drug Target Review's Editor Victoria Rees brings you the highlights from the American Association for Cancer Research Meeting 2022.
Pfizer has announced its acquisition of ReViral to advance disease research and development with a complementary strategy to help improve patient outcomes through treatment for respiratory syncytial virus infections and prevent illness through vaccination.
Pre-clinical research from VBI Vaccines has demonstrated an encouraging ability to boost and broaden the immune response against the coronavirus Beta variant.
New research has shown iron-like compound holds promise for treating patients with glioblastoma, an aggressive brain cancer.
Looking at disease through a patient’s memory B cells can reveal vulnerabilities within pathogens. In this article, Dr Purnanand Sarma, President and Chief Executive Officer of Immunome, explores how advancements in memory B-cell antibody-based treatments will improve our understanding of how these cells can aid in fighting cancer and other diseases.
A new study by University of Texas Health Science Center at San Antonio has found that boosting liver mRNAs in obese mice reduces appetite and body weight.
